000			01846 a2200493 4500
005			20250514161618.0
264		0	_c20040324
008			200403s 0 0 eng d
022			_a1064-1297
024	7		_a10.1037/1064-1297.11.4.276 _2doi
040			_aNLM _beng _cNLM
100	1		_aPiasecki, Thomas M
245	0	0	_aSmoking withdrawal dynamics: III. Correlates of withdrawal heterogeneity. _h[electronic resource]
260			_bExperimental and clinical psychopharmacology _cNov 2003
300			_a276-85 p. _bdigital
500			_aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdministration, Cutaneous
650	0	4	_aBupropion _xtherapeutic use
650	0	4	_aChi-Square Distribution
650	0	4	_aDopamine Uptake Inhibitors _xtherapeutic use
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aNicotine _xadverse effects
650	0	4	_aNicotinic Agonists _xadverse effects
650	0	4	_aPredictive Value of Tests
650	0	4	_aPsychiatric Status Rating Scales
650	0	4	_aRecurrence
650	0	4	_aSeverity of Illness Index
650	0	4	_aSmoking
650	0	4	_aSmoking Cessation _xmethods
650	0	4	_aSubstance Withdrawal Syndrome _xdrug therapy
650	0	4	_aTime Factors
650	0	4	_aTobacco Use Disorder _xdrug therapy
650	0	4	_aTreatment Outcome
700	1		_aJorenby, Douglas E
700	1		_aSmith, Stevens S
700	1		_aFiore, Michael C
700	1		_aBaker, Timothy B
773	0		_tExperimental and clinical psychopharmacology _gvol. 11 _gno. 4 _gp. 276-85
856	4	0	_uhttps://doi.org/10.1037/1064-1297.11.4.276 _zAvailable from publisher's website
999			_c14337187 _d14337187